Monday, October 20, 2025 10/20/2025

Home-based plasma self-collection device for remote diagnosis and monitoring of AD-associated biomarkers

Award Number: R43AG097214
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2025
PERIOD OF PERFORMANCE END DATE: 09/24/2026

Group Awards By:

View Award Description

Home-based plasma self-collection device for remote diagnosis and monitoring of AD-associated biomarkers - Project Summary/Abstract Lo Bio has developed the P1™, a microtube that collects whole blood and separates it into lab quality cell-depleted liquid plasma at the point-of-draw. Our innovation uses proprietary magnetic beads designed to capture and separate blood cells from plasma in 1 min with over 99.9% efficiency. The P1 will enable the collection of laboratory-quality, high-yield, and stable plasma in essentially any remote environment and at a low cost. While the P1 can improve access to diagnostics broadly, industry experts suggest to us that helping to diagnose and monitor participants of clinical studies for Alzheimer’s Disease (AD) is one of the most important applications today. In particular, demonstrating its compatibility with the p-Tau 217 biomarker is highly important given that it is one of the most studied biomarkers and is recognized by the scientific and clinical communities as one of the most promising biomarkers for AD diagnosis and monitoring. In this application we propose to advance key elements of the P1 technology, including optimize antibody binding efficiency, demonstrate sample biocompatibility with p-Tau 217 analysis, and conduct pre-clinical validation comparing P1-separated plasma against centrifuged plasma for plasma quality. Aim #1. Develop Custom aRBC Monoclonal Antibody. We will work with Lampire Biologicals to develop a custom mouse monoclonal antibody and demonstrate comparable plasma quality to centrifugation. Aim #2: Conduct equivalence and sample stability study. To validate use for AD clinical trials, we will demonstrate strong correlation (R>0.9) between P1 and centrifuged plasma for p-tau 217 quantitation. We will also conduct a 3-day stability study to demonstrate that ptau217 is stable in P1 plasma for at least 24 hours of simulated shipping (<15% bias). Aim #3: Complete implementation study. We will conduct a 15-person usability and analytical study to validate that self-collected plasma produced by the P1 is suitable for use in decentralized settings. Success is defined as having >90% successful use of P1 by lay-users and >95% equivalency between P1 and centrifuged plasma.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $305,621 )
2025	2025	LO BIOSCIENCES, INC.	12358 PARKLAWN DR STE 280	ROCKVILLE	MD	20852	MONTGOMERY	USA	Aging Research	000	1	9/23/2025	NEW	$305,621
														Subtotal = $305,621

Grand Total All Awards = $305,621

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Home-based plasma self-collection device for remote diagnosis and monitoring of AD-associated biomarkers

Award Number: R43AG097214

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2025

PERIOD OF PERFORMANCE END DATE: 09/24/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer